The overall hypothesis for this project is that increased mitochondrial generation of superoxide causes a disruption of vascular smooth muscle heme biosynthesis by ferrochelatase (FECH), resulting in a loss of the beneficial vascular regulatory effects of soluble guanylate cyclase (sGC). It is known that oxidation of the sGC heme promotes loss of regulation by nitric oxide (NO) and sGC degradation by proteolysis. While the mitochondrial heme generating enzyme FECH has an iron-sulfur cluster essential for its stability, which is a potential target for disruption by superoxide, the literature appears to ack evidence for the consequences of FECH dysfunction on the heme-dependence of sGC regulation in any biological system. Due to the potential importance of angiotensin II (AngII) in promoting human vascular dysfunction in multiple diseases and previous evidence for mechanisms associated with increased superoxide generation in subcellular sites including mitochondria, and disruption of NO and its associated heme-dependent regulation of sGC/cGMP-mediated vasodilation, we hypothesized and found evidence for both FECH activity being disrupted by AngII and for FECH controlling the expression and NO-mediated activation of sGC. Studies in Aim 1 focus on showing how AngII regulation of increases in mitochondrial superoxide cause a disruption in heme biosynthesis by FECH that impairs vascular regulation by sGC in isolated mouse and bovine coronary arteries treated with AngII and siRNA or mechanistic probes modulating subcellular sources of superoxide and FECH. Arteries from mice deficient in AngII type-1 receptor (AT1R), Cu, Zn-SOD (SOD1), mitochondrial matrix SOD2, FECH, Nox1 and Nox2 oxidase will be used in these studies to define how AngII regulation of cytosolic and mitochondrial superoxide influences regulation by the sGC and FECH systems.
Aim 2 investigates new preliminary observations suggesting how promoting availability of protoporphyrin IX (PpIX, an activator of sGC) and heme from ?-aminolevulinic acid (ALA) appears to protect ferrochelatase and sGC regulation potentially through a cGMP-mediated inhibition of mitochondrial superoxide that may involve cGMP preventing the depletion of SOD2. Studies in Aim 3 focus in defining the in vivo importance of the disruption of ferrochelatase and heme- associated sGC regulation of vascular function and protection provided by ALA, using a mouse model of osmotic minipump delivery of AngII. Radiotelemetry monitoring of blood pressure, echocardiography, and evaluation of changes in isolated arteries and in vivo arteriolar function in the skeletal muscle microcirculation will be evaluated. The role of subcellular sources of superoxide in the disruption of ferrochelatase will also be assessed in AngII-infused mice deficient in AT1R, SOD1, SOD2, Nox1 and Nox2, together with a therapy specifically targeting mitochondrial superoxide. These studies are expected to document that mitochondrial superoxide disruption of ferrochelatase has an important role in sGC-associated vascular dysfunction, which can be targeted with a beneficial ALA therapy regulating the activity, expression and NO-stimulation of sGC.

Public Health Relevance

This project investigates the novel observation that vascular diseases associated with increased angiotensin II could promote the loss of a key protective vasodilator system (guanylate cyclase activation by nitric oxide) as a result of disrupting the production of a needed heme cofactor made by mitochondria. It also investigates a potential novel therapeutic approach based on treatment with an amino acid normally used to produce heme, because it appears to have disease reversing beneficial effects.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL129797-03
Application #
9432551
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Charette, Marc F
Project Start
2016-04-01
Project End
2020-02-29
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
New York Medical College
Department
Physiology
Type
Graduate Schools
DUNS #
041907486
City
Valhalla
State
NY
Country
United States
Zip Code
10595
Gupte, Sachin A; Wolin, Michael S (2017) Mitochondrial Calcium Transport: A Potentially Prominent, Therapeutically Targetable Contributor to Pulmonary Arterial Hypertension Progression. Am J Respir Crit Care Med 195:420-421
Kandhi, Sharath; Zhang, Bin; Froogh, Ghezal et al. (2017) EETs promote hypoxic pulmonary vasoconstriction via constrictor prostanoids. Am J Physiol Lung Cell Mol Physiol 313:L350-L359
Froogh, Ghezal; Pinto, John T; Le, Yicong et al. (2017) Chymase-dependent production of angiotensin II: an old enzyme in old hearts. Am J Physiol Heart Circ Physiol 312:H223-H231
Sun, Angela; Huang, An; Kertowidjojo, Elizabeth et al. (2017) Divergent outcomes of fructose consumption on exercise capacity of rats: friend or foe. J Appl Physiol (1985) 122:368-375
Patel, Dhara; Lakhkar, Anand; Wolin, Michael S (2017) Redox Mechanisms Influencing cGMP Signaling in Pulmonary Vascular Physiology and Pathophysiology. Adv Exp Med Biol 967:227-240
Kandhi, Sharath; Froogh, Ghezal; Qin, Jun et al. (2016) EETs Elicit Direct Increases in Pulmonary Arterial Pressure in Mice. Am J Hypertens 29:598-604
Ochi, Rikuo; Dhagia, Vidhi; Lakhkar, Anand et al. (2016) Rotenone-stimulated superoxide release from mitochondrial complex I acutely augments L-type Ca2+ current in A7r5 aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 310:H1118-28
Qin, Jun; Le, Yicong; Froogh, Ghezal et al. (2016) Sexually dimorphic adaptation of cardiac function: roles of epoxyeicosatrienoic acid and peroxisome proliferator-activated receptors. Physiol Rep 4:
Ratliff, Brian B; Abdulmahdi, Wasan; Pawar, Rahul et al. (2016) Oxidant Mechanisms in Renal Injury and Disease. Antioxid Redox Signal 25:119-46
Froogh, Ghezal; Qin, Jun; Kandhi, Sharath et al. (2016) Female-favorable attenuation of coronary myogenic constriction via reciprocal activations of epoxyeicosatrienoic acids and nitric oxide. Am J Physiol Heart Circ Physiol 310:H1448-54

Showing the most recent 10 out of 13 publications